617 related articles for article (PubMed ID: 26471348)
21. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M
Oncology; 2013; 84(2):108-14. PubMed ID: 23147476
[TBL] [Abstract][Full Text] [Related]
24. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
27. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
29. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
31. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY; Chao Y
Int J Cancer; 2013 May; 132(10):2448-58. PubMed ID: 23129123
[TBL] [Abstract][Full Text] [Related]
32. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2016 Apr; 34(2):255-60. PubMed ID: 26769245
[TBL] [Abstract][Full Text] [Related]
33. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
34. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Doyle A; Marsh P; Gill R; Rodov M; Mohsen W; Varma P; Hong T; Strasser SI; Bell S; Ryan M; Nicoll A; Lubel J; Gow PJ; Fink MA; Roberts S; Kemp W; Kronborg I; Arachchi N; Knight V; Dev A
Scand J Gastroenterol; 2016 Aug; 51(8):979-85. PubMed ID: 27161568
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
Branco F; Alencar RS; Volt F; Sartori G; Dode A; Kikuchi L; Tani CM; Chagas AL; Pfiffer T; Hoff P; Carrilho FJ; Mattos AA
Ann Hepatol; 2017; 16(2):263-268. PubMed ID: 28233750
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Zhao Y; Wang WJ; Guan S; Li HL; Xu RC; Wu JB; Liu JS; Li HP; Bai W; Yin ZX; Fan DM; Zhang ZL; Han GH
Ann Oncol; 2013 Jul; 24(7):1786-1792. PubMed ID: 23508822
[TBL] [Abstract][Full Text] [Related]
39. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
40. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
